Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases: Epidemiological Data on Smoking and Preclinical and Clinical Data on Nicotine provides a comprehensive summary of the epidemiological data on smoking and several neurological disorders, including Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Tourette's syndrome, schizophrenia, anxiety, depression and ADHD, as well as preclinical and clinical data on the effects of nicotine. Despite the obvious and undisputed harmful nature of smoking, evidence suggests that some tobacco and tobacco smoke-derived constituents may offer neuroprotective effects, possibly in combinations, rather than individually.

This unprecedented book describes the complex relationships between smoking and neurological disease and the bioactive compounds found in tobacco. It provides a comprehensive review of nicotine and other compounds found in tobacco plant, with scientific evidence of neuroprotective and anti-inflammatory effects that may act in conjunction with nicotine to exert neuroprotective effects observed in smokers. View more

Key Features
Presents the first comprehensive, tabulated summary of literature on the epidemiological data on smoking and neurological disease
Includes preclinical and clinical data on nicotine in neurological diseases and mechanisms of action of nicotine in neuroprotection
Features a comprehensive summary of non-nicotine smoke constituents with potentially neuroprotective and anti-inflammatory properties
Discusses Multiple Sclerosis, Alzheimer's disease, Parkinson's Disease, Schizophrenia, Depression, ADHD, Anxiety and Tourette's Syndrome in the context of smoking and nicotine
Readership
Neuroscientists, neurobiologists, neurologists, toxicologists, pharmaceutical scientists, post-doctoral fellows, researchers, graduate students in biological and biomedical sciences

Table of Contents
Foreword

Introduction

Search Methods

Parkinson's disease
-Symptoms and epidemiology of Parkinson's disease (high level), molecular mechanisms and focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

Alzheimer's disease
-Symptoms and epidemiology of Alzheimer's disease (high level), molecular mechanisms and focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

Multiple sclerosis
-Symptoms and epidemiology of multiple sclerosis, molecular mechanisms and impact of smoking and nicotine Tourette syndrome

Schizophrenia
-High level description of symptoms and epidemiology of the disease, some molecular mechanisms, impact of smoking with clinical evidences, impact of nicotine with clinical and non-clinical evidences

Tourette syndrome
-Symptoms, epidemiology and potential causes of Tourette's syndrome (high level), focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

Attention Deficit Hyperactivity Disorder
-Symptoms, epidemiology and potential causes of ADHD (high level), focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

Depression
-Symptoms, epidemiology and potential causes, impact of smoking and nicotine

Anxiety
-Symptoms, epidemiology and potential causes, impact of smoking and nicotine

Nicotine
-Impact of nicotine on cognitive functions, nicotinic acetylcholine receptors, nicotine effects on neurotransmitter systems and on cellular molecular signaling, nAChRs in mitochondria, nAChRs in neural stem cells and in microglia and transmembrane transport of nicotine

Other Compounds from Tobacco with Potential Impact on Neurodegenerative Diseases
-nAChRs agonists, MAO inhibitors in therapy of neurodegenerative diseases, other tobacco compounds and neuroprotection: Cotinine, Anatabine, anabasine and other tobacco alkaloids, Cembranoids, Scopoletin, Eugenol, Rutin, Ferulic acid, Chlorogenic acid, -Carboline, Resorcinol, -sitosterol, Quinoline, Sinapyl alcohol, Caffeic acid

Research Models of Neurodegenerative Diseases: Major Considerations for Translatibility


Concluding Remarks